Abstract: Methods of controlling biological processes by altering the electric field gradient in a test chamber are disclosed. A portion of a surface of the test chamber is attached to at least one immobilized component of the biological process. Microfluidic devices capable of same are also disclosed.

Abstract: Methods of generating a synthetic embryo are provided. Accordingly, there is provided a method of generating a synthetic embryo comprising inducing expression of a factor that induces differentiation to trophectoderm cells in a subpopulation of naïve pluripotent stem cells (PSCs) to obtain a trophectoderm primed cells; inducing expression of a factor that induces differentiation to extra embryonic primitive endodermal cells in a second subpopulation of naïve PSCs to obtain extra embryonic primitive endodermal primed cells; and mixing said trophectoderm primed cells and said extra embryonic primitive endodermal primed cells with naïve PSCs under conditions that allow formation of aggregated cells. Also provided are articles of manufactures, mixtures and aggregates of cells and methods of using same.

Abstract: Disclosed herein are genetically modified plants having altered biological activity of 3-?-hydroxysteroid dehydrogenase/isomerase (GAME25), or 2-oxoglutarate-dependent dioxygenase (GAME31), or a combination thereof, wherein the genetically modified plants have an altered content of at least one cholesterol derived compound selected from the group including a steroidal alkaloid or a glycosylated derivative thereof and an unsaturated or saturated steroidal saponin or a glycoside derivative thereof. Further disclosed herein are genetically modified plants having altered expression of a gene encoding a 3-?-hydroxysteroid dehydrogenase/isomerase (GAME25), or a 2-oxoglutarate-dependent dioxygenase (GAME31), or a combination thereof, wherein the genetically modified plant has an altered content of at least one cholesterol derived compound selected from the group including a steroidal alkaloid or a glycosylated derivative thereof and an unsaturated or saturated steroidal saponin or a glycoside derivative thereof.

Abstract: The present invention provides humanized monoclonal antibodies that specifically recognize human QSOX1 and inhibit its activity. The humanized antibodies of the present invention were designed following in-silico selection of specific variable region segments, based on their energy scores, and were produced and confirmed to function properly in binding and inhibiting human QSOX1. The present invention further provides pharmaceutical compositions comprising the humanized antibodies and methods for their use in cancer therapy and diagnosis.

Abstract: Provided is a plant exudate, methods for obtaining a plant exudate by inducing the plant to secrete an exudate and systems for the collection of a plant exudate which include: one or more plant container including at least two discrete compartments each configured to accommodate a split root of a plant, the compartments being a root stimulating compartment including one or more input being in fluid communication with at least a source of a plant root stimulant, and a root exudate harvesting compartment, and a root exudate collection compartment in fluid communication with the root exudate harvesting compartment.

Abstract: Provided herein a biodegradable composite comprising a biodegradable polymer and bio-crystals, wherein the bio-crystals are in a concentration of between 1 wt % to 50 wt % of the biodegradable polymer.

Abstract: A system and methods for electron beam imaging or electron beam spectroscopy. The system comprising: a transmission electron microscope (TEM) having a back focal plane; one or more laser-based devices, configured to shift a predetermined portion of an electron wave to an energy that is different from the energy originally provided by the electron source of the TEM; and an electron energy filter that is configured to accept electron waves, at the energy provided by the electron source of the TEM, and further configured to reject electron waves shifted to a different energy by the laser device.

Abstract: Methods of treating a disease or disorder associated with a down or up-regulation of an immune response of a subject are disclosed. The methods comprising administering to the subject a therapeutically effective amount of any one or more of the molecule 1?-2? glycosyl cyclic adenosine diphosphate ribose (1?-2? gcADPR), 1?-3? gcADPR or Tad1 protein.

Abstract: Provided herein a supramolecular assembly comprising a solid porous particle comprising a single-stranded polynucleotide encapsulated by non-covalent organic structure. Specifically, the non-covalent organic structure is melamine-cyanurate, and the single-stranded polynucleotide is ssDNA or ssRNA.

Abstract: A polymeric compound is disclosed herein, having the general formula I: wherein m, n, X, Y, Z and L are as defined herein. Further disclosed herein are lipid bilayers comprising at least one bilayer-forming lipid and the aforementioned polymeric compound, and liposomes comprising such a bilayer, as well as methods, uses and compositions utilizing such bilayers and/or liposomes for reducing a friction coefficient of a surface and/or for inhibiting biofilm formation.

Abstract: Genetically modified phages are provided. Accordingly, there is provided a genetically modified phage comprising a polynucleotide encoding an anti-defense system polypeptide. Also provided are methods of producing and using same.

Abstract: This invention is directed to a method of electrocatalytic reduction of dinitrogen (N2) to ammonia using a poly oxometalate catalyst, an alkali metal cation and a donor of a proton and/or an electron.

Abstract: A quantum computing system, method, and computer readable medium involves initializing a state of a resonator-coupled quantum emitter having at least four levels arranged in an N-configuration, the N-configuration having a first ground state, a second ground state, a first excited state and a second excited state. A frequency of a first transition between the first ground state and the first excited state is tuned, a frequency of a second transition between the second ground state and the second excited state is tuned, and a frequency of a third transition between the second ground state and the first excited state is tuned. A plurality of photons are fed at a frequency corresponding to the frequency of the second transition, thereby entangling the plurality of photons to the resonator-coupled quantum emitter.

Abstract: Systems and methods for a quantum computing include a plurality of photonic processing stages, a plurality of heralding-free connections, and circuitry configured to regulate photon flow between adjacent stages such that decisions about stage settings or flow between adjacent stages are free of input from a previous stage. Each heralding-free connection is located between adjacent photonic processing stages. Each photonic processing stage includes at least two of an optical switch, a beam splitter, a waveguide or a photon generator. Methods include transmitting or receiving a plurality of photons via a plurality of heralding-free connections, and regulating photon flow between adjacent stages such that decisions about stage settings or flow between adjacent stages are free of input from a previous stage.

Abstract: A quantum computing system, method and computer readable medium involve a vacuum enclosure for sustaining a vacuum below 10?3 millibar, optical resonators tuned to a resonance of an alkali atom, and a trapping laser for maintaining the alkali atom within a mode of the optical resonators. An atom excitation laser induces photon emissions, a plurality of waveguides couple photons to and from the optical resonators, and a plurality of detectors detect a presence or absence of an atom-resonator coupling. A processor receives output signals from the detectors and controls optical switches for switching between two or more of the plurality of waveguides.

Abstract: Methods of controlling biological processes by altering the electric field gradient in a test chamber are disclosed. A portion of a surface of the test chamber is attached to at least one immobilized component of the biological process. Microfluidic devices capable of same are also disclosed.

Abstract: The present invention relates to a quantum computing device based on manipulating Majorana Zero Mode excitations (MZMs) in topological superconducting regions formed in a tapered nanowire or similar structure. The tapering of the NW structure results in the formation of discrete regions of topological superconductivity having MZMs at their end boundaries, and thereby facilitates establishing the MZMs without delicate tuning procedures. A quantum swap gate is provided, utilizing two such structures in contact and disposed orthogonally to one another. Applying a magnetic field selectively lengthens the region of one structure while shortening the region of the other, allowing voltage and magnetic field changes to manipulate and interchange the MZM quantum states of the two structures to effect the swap operation.

Abstract: A method of analyzing the likelihood of weight regain in a subject who has reached a target weight by practicing a weight loss program is disclosed. The method comprises determining an amount or presence of at least one microbe and/or product thereof in the gut microbiome of the subject, wherein the amount of the at least one microbe is altered during a prior weight gain period of the subject to reach a level representative of an obese subject and further wherein the amount of the at least one microbe is retained at the level following the weight loss program, wherein the amount or presence of the at least one microbe or product thereof is predictive of weight regain.

Abstract: A method of treating a malignant disease involving T cell exhaustion in a subject, with the proviso that said malignant disease is not a B cell malignancy, is disclosed. The method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84, thereby treating the malignant disease involving the T cell exhaustion. Also disclosed is a method of treating an autoimmune or inflammatory disease in a subject, the method comprising administering to a subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of CD84. A method comprising administering to the subject a therapeutically effective amount of an agent capable of decreasing an activity or expression of SLAMF1, with the proviso that said agent is not an agent capable of decreasing an activity or expression of CD84, is also disclosed.

Abstract: This invention provides nanostructures comprising a base. and nano-protrusions attached to the base. The invention further provides arrays of such nanostructures on substrates. Also provided by this invention are analysis and catalysis. separation and purification systems and methods. comprising or making use of the novel nanostructures. Particles and films comprising nano-protrusions are included in this invention as well.